98%
921
2 minutes
20
Introduction: This study evaluates the clinical value of a deep learning-based artificial intelligence (AI) system that performs rapid brain volumetry with automatic lobe segmentation and age- and sex-adjusted percentile comparisons.
Methods: Fifty-five patients-17 with Alzheimer's disease (AD), 18 with frontotemporal dementia (FTD), and 20 healthy controls-underwent cranial magnetic resonance imaging scans. Two board-certified neuroradiologists (BCNR), two board-certified radiologists (BCR), and three radiology residents (RR) assessed the scans twice: first without AI support and then with AI assistance.
Results: AI significantly improved diagnostic accuracy for AD (area under the curve -AI: 0.800, +AI: 0.926, < 0.05), with increased correct diagnoses ( < 0.01) and reduced errors ( < 0.03). BCR and RR showed notable performance gains (BCR: < 0.04; RR: < 0.02). For the diagnosis FTD, overall consensus ( < 0.01), BCNR ( < 0.02), and BCR ( < 0.05) recorded significantly more correct diagnoses.
Discussion: AI-assisted volumetry improves diagnostic performance in differentiating AD and FTD, benefiting all reader groups, including BCNR.
Highlights: Artificial intelligence (AI)-supported brain volumetry significantly improved the diagnostic accuracy for Alzheimer's disease (AD) and frontotemporal dementia (FTD), with notable performance gains across radiologists of varying expertise levels.The presented AI tool is readily clinically available and reduces brain volumetry processing time from 12 to 24 hours to under 5 minutes, with full integration into picture archiving and communication systems, streamlining the workflow and facilitating real-time clinical decision making.AI-supported rapid brain volumetry has the potential to improve early diagnosis and to improve patient management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632536 | PMC |
http://dx.doi.org/10.1002/dad2.70037 | DOI Listing |
Neuropeptides
September 2025
Department of Physiology and Cell Biology, The National Institute for Biotechnology in the Negev, and the School of Brain Sciences and Cognition, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Despite extensive research into Alzheimer's disease (AD), few therapeutic strategies have successfully addressed its core pathology at the synaptic level. Small peptides represent a promising class of therapeutic agents capable of modulating key molecular pathways involved in amyloid toxicity, tau hyperphosphorylation, and synaptic degeneration. Their unique ability to cross biological barriers, interact with intracellular targets, and be modified for enhanced stability positions them as viable candidates for next-generation treatments targeting cognitive decline in AD.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Department of Emergency and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, #1055 Sanxiang Road, Suzhou 215004, Jiangsu, China. Electronic address:
β-Glucan, a polysaccharide from Saccharomyces cerevisiae with immunomodulatory activities that may not trigger pro-inflammatory responses in microglia, has been reported to show rapid antidepressant effects in chronically stressed animals by restoring microglial function in the dentate gyrus. However, the mechanisms underlying this effect of β-glucan are still largely unclear. Considering the importance of astrocytic purinergic 2Y1 receptors (P2Y1Rs) and brain-derived neurotrophic factor (BDNF) in the antidepressant effects of microglial stimulation, we hypothesize that β-glucan produces antidepressant effects by mobilizing astrocytic P2Y1R-triggered BDNF signaling in the hippocampus.
View Article and Find Full Text PDFBiochem Pharmacol
September 2025
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. Electronic address:
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor in adults, characterized by rapid growth, diffuse infiltration, and a dismal prognosis. Despite aggressive treatment involving maximal surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy, therapeutic outcomes remain poor due to intrinsic and acquired resistance. Autophagy, a catabolic process that degrades damaged cellular components, plays a critical role in this resistance by enabling tumor cells to survive under metabolic, hypoxic, and therapeutic stress conditions.
View Article and Find Full Text PDFNeuroscience
September 2025
Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China. Electronic address:
The auditory brainstem response (ABR) remains the gold standard for evaluating hearing function in both animal models and humans. Features of ABR, including threshold, wave I amplitude and latency are critical for diagnosing and investigating the mechanisms of hearing loss. Critically, the rapid proliferation of genetically engineered mouse models in hearing research has created an imperative demand for high-throughput ABR testing capabilities.
View Article and Find Full Text PDFBrain Topogr
September 2025
School of Biomedical Sciences, University of New South Wales (UNSW), Wallace Wurth Building, Kensington, NSW, 2052, Australia.
Different levels of reduced consciousness characterise human sleep stages at the behavioural level. On electroencephalography (EEG), the identification of sleep stages predominantly relies on localised oscillatory power within distinct frequency bands. Several theoretical frameworks converge on the central significance of long-range information sharing in maintaining consciousness, which experimentally manifests as high functional connectivity (FC) between distant brain regions.
View Article and Find Full Text PDF